Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use. Issue 5 (3rd September 2018)

• Record Type: Journal Article
• Authors: Melnick, Stephen; Rajagopalan, Priya; Lynn, Theresa; Donato, Anthony
• Is Part Of: Journal of community hospital internal medicine perspectives. Volume 8:Issue 5(2018)
• Page Start: 315
• Page End: 316
• Publication Date: 2018-09-03
• Subjects: Sodium glucose co-transporter inhibitor -- SGLT2 inhibitor -- genitourinary infections; Internal medicine -- Periodicals; Hospitals -- Periodicals; Hospitals, Community; Internal Medicine; Hospitals; Internal medicine; Periodicals; Periodicals; 610
• DOI: 10.1080/20009666.2018.1527667
• Languages: English
• ISSNs: 2000-9666

Abstract

ABSTRACT: Context : Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a novel treatment approved for type 2 diabetes mellitus to lower hyperglycemia, systolic blood pressure, and promote weight loss. Commonly reported serious adverse events include increased mycotic urogenital infections, orthostatic hypotension, and normoglycemic ketoacidosis. Case report : We present a case of a 47-year old man with a history of type 2 diabetes mellitus initiated on the SGLT-2 inhibitor canagliflozin preoperatively before a penile implant, who presented with late postoperative MRSA bacteremia and scrotal abscess requiring implant extraction. Conclusion : As the SGLT-2 inhibitors are gaining in popularity, prescribers must be aware of the potential adverse genitourinary infectious outcomes. Providers should use caution and avoid initiating SGLT-2 inhibitors in the perioperative setting, and may even consider holding or discontinuing this medication in the setting of impending GU surgery.